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Sinary We asessed factors which affect cisplatin concentrations in human surgical tumour specmen.
Cisplatmn 10mg m 2 was given i.v. to 45 consenting patients undergoing surgical resection of neoplasms, and
platinum was assayed reted tumour and deprotnated plasma by flameless atomic absorption
spectrophotometry. By multiple stepwise regression analysis of normahsed data, patient characteristics that
emerged as being most closely associated (P <0.05) with tumour platinum concentrations (after correcting for
associations with other variables) were tumour 'source' [primary brain lymphomas, medullastomas and
meningiomas (type LMM)>'others'>lung cancer> head/neck cancer> gliomas) or tumour 'type'
(LMM> brain metastases>extracerebral tumours> gliomas), serum calcium and chloride (positive correla-
tions) and bilirubin (negtive). Tumour location (intracranial vs extracranial) did not correlate with platinum
concentrations. If values for a single outlier were omitted, high-grde gliomas had significantly higher platinum
concentrations (P <0.003) than low-grade gliomas. For intracranial tumours, the computerised tomographic
scan feature that correlated most closely with platinum concentrations in multivariate analysis was the
darkness of peritumoral oedema. Tumour source or type is a much more important correlate of human
tumour cisplatin concentrations than is intracranial vs extacranial location. Serum calcium, chloride and
bilirubin levels may affect tumour cisplatin uptake or retention. CT scan characteristcs may help predit
cisplatin concentrations in intacranial tumours.
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It remains uncetain if the blood-brain barrier (BBB) plays a
major role in the resistance of intracranial (IC) tumours to
chemotherapy (reviewed in Stewart et al., 1994a; Stewart,
1994). For many chemotherapy drugs, only low concentra-
tions are found in normal brain and cerebrospinal fluid
(CSF), because of the BBB and blood-CSF barrier, but the
barrier is often largely disrupted in patients with brain
tumours (Blasberg and Groothuis, 1986). In animal models,
the degree of BBB disruption varies from one type of tumour
to another and between parts of the same tumour (Groothuis
et al., 1981; Blasberg and Groothuis, 1986). Lower concen-
trations of chemotherapy drugs (Levin et al., 1972; Tator,
1976; Groothuis et al., 1981) and lower capillary permeability
(Hasegawa et al., 1983) have been reported in animal IC
tumours compared with subcutaneous tumours. Moreover,
some studies have reported that drug distribution is far more
uniform in extracranial (EC) tumours than in IC tumours
(Tator, 1976; Groothuis et al., 1981), and it has been argued
that this may result in reistance in the areas of IC tumours
that achieve only low drug concentrations. However, data
supporting a difference between IC and EC tumours with
respect to uniformity of drug distribution are limited, and
other studies have suggested that drug distribution also varies
markedly within EC tumours (Rowe-Jones, 1969). Further-
more, if drug distrubution were less uniform in IC tumours
than in EC tumours, one would also expect that the mean
concentration in IC tumours would be less than in EC
tumours: for the mean drug concentrations to be similar, one
would have to have areas of unusually high concentrations of
drug in IC tumours, as well as having areas of unusually low
concentrations. It would be difficult to explain why one
would have areas of unusually high drug concentrations in
IC tumours.
It has also been argued that resistance of IC tumours may
be due in part to invasion of tumour cells into the brain
adjacent to tumour (BAT), where the BBB is more intact,
and where drug concentrations are lower than in the main
body of the tumour (Levin et al., 1975). However, the impor-
tance in brain tumour chemotherapy of resistance of tumour
cells in the BAT remains controversial. Since even small
numbers of tumour cells may induce leakiness in local blood
vessels (Stewart et al., 1987), small tumour deposits in the
BAT could result in a very localised increase in drug concent-
rations, and it is uncertain how drug concentrations compare
in individual tumour cells in BAT vs the main tumour body.
We have studied several chemotherapy drugs with respect
to the concentrations reached in human IC tumours (re-
viewed in Stewart et al., 1994a, Stewart, 1994). Concentra-
tions in IC tumours appeared to be similar to those in EC
tumours for cisplatin, phosphonacetyl-L-aspartate, 4'-(9-
acridinylamino)-methanesulphon-m-aniside (AMSA), penta-
methylmeamine, doxorubicin and vinblasine. Concen-
trations of etoposide and mitoxantrone in IC tumours were
somewhat lower than in EC tumours. Since no EC tumour
samples were available, comparisons were not possible for a
variety of other agents, but for most of these drugs poten-
tially cytotoxic concentrations were achieved in human IC
tumours. Low drug concentrations in normal brain and CSF
did not preclude high concentrations in IC tumours.
In this paper, we report the results of further studies of
human tumour accumulation of the chemotherapy drug cis-
platin. These studies were done since our earliest studies of
surgical specimens had looked only at IC tumours. While our
later autopsy studies had looked at both IC and EC tumours,
there were differences between patients with respect to drug
doses, time from last treatment to death, concurrent drugs,
etc. (reviewed in Stewart et al., 1994a; Stewart, 1994). Hence,
we conducted the studies reported in this paper so that a
companson could be made between IC and EC tumours
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Materials ad edon
Drug administration, sample collection andplatinm assay
Forty-five patients undergoing surgical excision of tumours
gave written informed consent to receive a non-toxic dose
(10 mgm-) of cisplatin i.v. before or during surgery. (None
of thes 45 patients had been included in our previously
published series on human tumour platinum concentrations).
Cisplatin was given in 50ml of normal saline over 15min,
ending between 5 min and 6 h (median, 1.25 h) before
tumour resection. Resected tumour that was not needed for
pathology studies was stored frozen (- 50-C) until assayed
for platinum. Time from drug infusion to tumour removal
was recorded. Blood samples were also obtained before cis-
platin infusion and after cisplatin infusion at 0, 2, 4, 6, 8, 10,
15, 20, 30 and 45 min and at 1, 2 and 3 h and at the time of
tumour removal. Blood samples were put on ice, then centri-
fuiged in a refrigerated centrifuge within 15 min. Red blood
cells were discarded. Plasma samples were immediately de-
proteinated by adding perchloric acid. (We have found that
the pharmacokinetics of cisplatin in deproteinated plasma is
essentially the same using the perchloric acid method of
deproteination as when using ultrafiltration; JM Molepo, R
Goel and DJ Stewart, unpublished data). The precipitate was
then removed by centrifuging in a Beckcman J2-21 refriger-
ated centrifuge. Tissue samples and deproteinated plasma
samples were assayed for platinum by flameless atomic
absorption spectrophotometry, using an electrotheimal
atomisation atomic absorption spectrometry system consis-
ting of a Varion Techtron AA-1745 spectrophotometer, a
GTA-95 graphite tube atomiser with an autosampler and an
Epson RX-80 printer (Stewart et al., 1994c). The instrument
conditions for the measurement of platinum were wavelength
265.9 nm, slit width 0.2 nm and lamp current 10 mA. Argon
was used as the sheath gas. The graphite tubes (which were
replaced after every 50 assays) were pyrolitically coated. Dur-
ing the drying step, the furnace temperature was 95C (ramp
15 s, hold 25 s). During the ashing step, the funace tempera-
ture was 1300 C (ramp 25 s, hold 20 s). During the atomise
step, the fiura temperature was 2700C (ramp 1 s, hold 2 s,
with an interal flow rate of 0 ml min-'). Matrix-matched
standards were prepared from a 1g 1-' solution of cisplatin
(PlatinoL Bristol-Myers Squibb Pharmaceuticals, Montreal,
Canada). Nitric acid (BDH, Toronto, Canada) was of analar
grade, and water was distillW and then deionised.
TLssue samples (0.2 g wet weight) were digested with 2.5 ml
of 70% nitric acid for 90min at 135-C in Teflon pressure
decomposition vessels with stainlss-steel casings (Gaffin,
1979). After cooling, the digests were washed quantitatively
into 20 ml glass beakers containing distilled deionised water,
and the contents evaporated to dryness on a hot plate. The
residues were allowed to dry, and were then dissolved in
1-2ml or 5ml of 0.5% (v/v) nitric acid, depending on
sample weight. Undissolved material was separated by means
of acrodisc filters (0.45 jam) attached to a syringe. An
intermediate platinum stock solution was used for calibrating
the instrument. It was prepared by dissolving a control tissue
sample in nitric acid, as above, then spiking the dissolved
control sample with the cisplatin injection solution to give a
concentration of 325 jig 1-'.
The instrm nt was calibrated with three working stan-
dards of 32.5, 65.0 and 130agI-1 by dispensing into the
graphite furnace 2, 4 and 8 ILI of intermediate stock solution,
made up in each case to 20jrl with 0.5% (v/v) nitric acid.
Sample solutions of 15Ill were also made up to a total
volume of 20pl, and then analysed for platinum using the
concentration mode of the spectrophotometer. Sample solu-
tions with concentration readings outside the calibration
range were diluted accordingly, then reanalysed. All
measurements were done in duplicte. After the analysis of
every two samples, the instrument was recalibrated with the
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intermediate working standard by a resloping procedure. The
lower limit of quantitation for this method was 0.051tg g-
Plasma pharmacokinetic parameters were estimated using a
computerised curve-stripping program (PKCALC) (Shu-
maker, 1986) with a Loo and Riegehnan (1970) correction
for infusion duration. Final values of pharmacokinetic
parameters were then derived by non-linear regression
analysis using the PCNONLIN computer program (Statis-
tical Consultants, 1986). Results were discarded for seven
patients with an R2<0.90.
CTscan assessment
For those patients with IC tumours, brain CT scans were
evaluated in a blinded fashion by one of the investigators
(DJS). The following parameters were estimated: volumes of
enhancement, of oedema (decreased attenuation outside of
tumour) and of the tumour 'necrotic' area (area ofdecreased
enhancement within the centre of an enhancing lesion); 'nec-
rotic' volume as a percentage of the total enhaning volume;
the maximum intensity of enhancement (0= none, 4=bone
density); the minimum intensity of enhancement within the
enhancing area; the maximum intensity of oedema (0= same
as normal brain, 4= as dark as ventricular fluid); lobe of the
brain in which the lesion was located; and closest proximity
of the enhaning lesion to outer surface of the brain and to
ventricle. For estimation of volumes, largest perpendicular
diameters were measured and multiplied by one another on a
given CT scan cut. Values obtained for different cuts were
then added together to give an estimate of volume. Volume
of oedema was calculated as the volume bounded by the
outer limits of areas of dcreased attenuation minus the
volume ofenhancement within the area ofdecreased attenua-
tion. It is stressed that all of these CT scan characteristics
involved relatively inexact, qualitative assesents rather
than exact quantitative measurements.
Statisticalanalyses
Several patient characteristics and treatment details were
recorded. For each of these factors, there were theoretical
reasons why they might potentially affect isplatin uptake
into tumours. These patient characteristics and treatment
variables were asse for their effect on tumour platinum
concentrations. Two-tailed t-tests (for dichotomous
variables), analysis ofvariance and Newman-Keuls multiple
comparison tests (for categorical variables), and Pearson
product-moment correlation coefficients (for continuous
variables) were used for univariate analyses. Continuous
dependent and independent variables that did not conform to
a normal distribution were normalised by truncation of the
values for up to three outliers and/or by log transformation
of the variable or by derivation of its square root.
We looked at the effect of tumour type on platinum con-
centrations in several ways, and used a variety of terms to
differentiate these ways from one another. Tumour platinum
concentrations were analysed as a functon of 'tumour type'
[EC tumour vs IC metastases vs gliomas vs primary IC
lymphomas- meningomas-medulloblastomas ('LMM': in-
cluded in a single group because of small numbers and
because of similarity in results)t 'tumour histopathology'
(adenocarcinomas vs squamous cell carcinomas vs gliomas vs
others), 'tumour source' (LMM vs lung vs head and neck vs
glioma vs others). In addition, tumour platinum concentra-
tions were analysed as a function of degree of tumour differ-
entiation (well vs poorly differentiated), necrotic vs vable
tumour, and tumour location in the brain for IC tumours (
parietal vs frontal vs occpital vs temporal vs cerebellar).
Pearson product-moment correlation coefficients were used to
correlate tumour platinum concentrations with plasma phar-
macokinetic parameters, with CT scan parameters, tumour
size estimated at the time of resection and with various
patient characteristics.Tinwd.pI& -
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Multiple stepwise regression analysis
Continuous variabls were normalised where necessary (as
outlined above), and multiple stepwise regression analysis
was used to assess which factors were independently most
closely associated with tumour platinum concentrations after
correcting for associations between independent variables.
Retsm
With respect to dichotomous and categorical patient vari-
ables, analysis of variance revealed that platnum concentra-
tions varied significantly (P <0.05) across the entire category
as a function of 'tumour type' (ranking order: LMM
group>brain metastases>extracranial tumours>gliomas),
'tumour histopathology' ('others'>adenocarcinomas
>squamous carcinomas>gliomas), and 'tumour source'
[non-small-cell lung cancer (NSCLC), tumours from 'other'
EC sources and the LMM group>head and neck cancers>
gliomas] (Table 1). In addition to differences being significnt
across the entire categories, Newman-Keuls multipk com-
parison tests also revealed that some of the differences
between individual tumour types were sin t (Table I).
Of note, tumour location (IC vs EC) appeared to have far
less of an impact on tumour platinum concentration than did
tumour histopathology and source. By multipk stepwise
regresiion analysis, 'tumour source' (as defined above) was
more important than either tumour histopathology or
locaton (IC vs EC).
Tumour grade may have had an effect on tumour platinum
accumulation for gliomas, but it did not have a significnt
impact for other tumour types. For gliomas, effect of tumour
grade is presented in Figure 1. If the results for all glioma
patients were included in statistical calulations, platinum
concentrations were not signiicantly different for high-grade
gliomas compared with low-grade gliomas. However, the
platinum concentration for one low-grade glioma was much
higher than those for all other low-grade gliomas. This
patient had an uncommon histopathological variant (a sub-
ependymal giant cell astrocytoma). If values for this one
outlier were omitted, differences between high-grade and low-
grade gliomas became statistically significnt for tumour
platinum concentrations. For other tumour types, tumour
platinum concentrations in pgg- g were 0.49 ± 0.19 in well-
differentiated squamous and adenocarcinomas (nine patients),
0.37 ± 0.07 in those that were poorly differentiated (nine
patients) and 0.36 ± 0.16 in those in whom tumour grade was
not speified (nine patients).
For IC tumours, lobe of the brain in which the tumour
was located had no significant effect on tumour platinum
concentrations.
Wlth respect to continuous variables, there was no correla-
tion between tumour platinum concentrations and any
plasma pharmacokinetic parameter. (Pharmacokinetic para-
meters are presented in Table H). Time from cisplatin
administration to tumour removal (normaised by log tras-
formation) did not vary signiiantly between different
tumour types, histopathologies or sources, and over the time
range of interest (5 min to 6h) it did not signiftly affect
tumour platinum concentrations. There was no correlation
between size of IC or EC tumour as estimated at the time of
resecion and tumour platinum concentrations. Table in
shows the Pearson product-moment correlation ceffients
for tumour platinum concentrations vs various other con-
tinuous indepnnt variables.
Using these independent variabks, we constructed several
multiple stepwise regression models to assess which factors
most closely correlated with tumour platinum concentrations
after correction for associations between the independent
variables. The model that best fitted our data is presented in
Table IV. Tumour type and serum calcium, bilirubin and
chloride levels each contributed significantly to the model.
(Tbe square root of chloride was used in the model since it
conformed to a normal distribution, unlike chloride itself.)
Taie I Tumour platinum concentrations: correlation with
dihotomous/categorical patient characteristics by t-tests and analysis
of variance
Tumour ptnum (aggg')`
Characteristic n Mean s.d.
Gender
Makl 26 0.39 0.16
Femak 19 0.41 0.23
Hydration (1)
<1 31 0.42 0.20
>1 14 0.35 0.16
Time of day of
cispltin administration (h)
0800-1200h 25 0.43 0.21
1200-1600 h 20 0.37 0.16
Dexamethasone
Yes 22 0.41 0.23
No 22 0.38 0.15
Dipkenylhydantoin
Yes 18 0.40 0.23
No 27 0.40 0.16
Tumour type
LMMc 5 0.57 0.l1
Brain etastases 7 0.48 0.25
Extracerebral 20 0.38 0.14
G;lomaf 13 0.32 0.21
Histology
Adenocarcinoma 7 0.48 0.23d'
Squamous carcinoma 18 0.37 0.13
Gliomat 13 0.32 0.21
Other 7 0.54 0.16
Tumour source
Non-small cell hmg 6 0.36 O.I9dx
Head and neck 15 0.36 0.11
Other ex anials 6 0.58 0.20
LMWM 5 0.57 0.11
Glioma 13 0.32 0.21
Tumour viability
V-iable 40 0.38 0.19
Necrotic 5 0.52 0.16
n, number of patients evaluable. a'Data were nornmahsed where
ner-ary by truncation of up to three outliers. b'MNograms of
platinum per gram wet weight of timsue. cLfMM, group composed of
primary central navous system lymphomas (two patiets),
edullobatomas (one patient) and meningomas (two patients).
dp <0.05 for the overal characteristic by t-test (for two groups) or
by analysis of variance (for more than two groups). eFor tumour
platinum concentrations, P-values for tumour typ histolgy and
tumor source we 0.04, 0.04 and 0.007 respectivey. By Newman-
Keuls multipk comparisons test, the only signiiant difference
between specific tumour types and histopathology groups was
between gliomas and 'other' histolgy when mean concentrations
were compared, but each tumour type and histology differed
sinificantly from eah other one when Kruskal-Walls mean ranks
were compard. With respect to tumour source, the LMM group and
tumours from 'other' EC pmary sites had higher mean platum
concentratios than did head and neck cancers and ghomas
(P <0.05). fLow-grade glioma (five patients) plus high-grade glioma
(eight patients). Ta cteonalclarcinoma of the blader (one
patient), troperitoneal sarcoma (one) and adenocarcinomas of the
kidney (two), colon (one) and breast (one).
For intracerebral tumours, platinum concentrations cor-
related with intensity of oedema on CT scan (r = 0.59,
P = 0.01) (Table V). The association of oedema intensity
with tumour platinum concentration continued to approach
significae (P = 0.06) even after correction for tumour
source by stepwise multiple regression analysis. Of interest,
assocations of tumour platinum concentrations with both
vohume of enh t and volume of oedema on CT
achieved staical signia (P = 0.002 for each) after
correcting for tumour source by multivariate analysis. How-
ever, if oedema intensity, volume of oedema and volume of
enhancement were entered together, the P-vahle remained
significnt only for oedema intensity, suggesting that it is theTumow dspl*ia upte
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Figue 1 Tumour platinum concentrations in gliomas as a func-
tion of tumour grade. Mean ± standard deviation platinum con-
centrations in jig g-' were: low-grade gliomas, 0.25 ± 0.28 (five
patients); low-grade glioma subgroup (one outlier with a
subependymal giant cell astrocytoma omitted), 0.12 ± 0.06 (four
patients), glioblastomas, 0.36 ± 0.16 (eight patients). The
difference between the low-grade glioma subgroup and the gliob-
lastoma group was significant (P = 0.003).
Tabl II Free plasma platinum pharmacokinetic parameters
Pharmacokinetic parameter Mean s.d.
Peak platinum concentration (ug ml-') 0.80 0.44
Half-life (h) 0.36 0.38
AUC (jLg h ml-') 0.37 0.23
Mean residence time (h) 0.52 0.55
Plasma clearance (h-'m-) 33.8 32.1
Volume of distribution (area) ( m-2) 12.1 7.9
most important CT scan vanrable in predicting tumour
platinum concentrations. Other CT scan features did not
correlate with tumour platinum concentrations in either
univariate or multivariate analysis.
Since only a low, subtherapeutic dose of cisplatin was
administered to these patients, and since only a small
minority of the patients went on to receive therapeutic doses
of cisplatin for recurrent tumour, it was not possible to
correlate tumour platinum concentrations with cisplatin anti-
tumour efficacy in individual patients.
D6cussion
These studies were done with a subtherapeutic cisplatin dose
since we wished to (and did) avoid toxicity. The drug was
being given strictly for the purposes of pharmacology studies
with no therapeutic intent. While it is highly unlikely that
exposure to a single low dose of cisplatin would result in
long-term cisplatin resistance, patients suspected pre-
operatively of having a chemotherapy-curable tumour type
were specificaDly excluded to preclude the possibility of resis-
tance induction. Hence, it is possible that our results would
not apply to tumour types that are generally highly respon-
sive to cisplatin.
We feel that the results obtained with these low-dose
studies may well be applicable to the higher doses usually
used clinicaly since the tumour platinum concentrations
noted in this study were in the expected range when com-
pared with our previous studies using higher doses of cis-
platin (reviewed in Stewart et al., 1994a; Stewart, 1994), since
cisplatin plasma pharmacokinetics is linear with dose (Ver-
morken et al., 1986), and since cisplatin accumulation in cells
in vitro is linear with dose and is not saturable (Mann et al.,
1990).
As in our previous studies, we measured only total
platinum concentrations in tissues. It is probable that a
Table m Tumour platinum concentrations: correlation with patient
characteristics by Pearson correlation coefficients'
Twnour platinwn
Patient characteristic n r P
Age 45 -0.10 0.50
Performance status (ECOG) 45 - 0.09 0.55
Systolic blood pressure 43 - 0.04 0.79
Diastolic blood pressure 43 - 0.07 0.67
Pulse rate 43 0.01 0.95
Temperature 30 0.17 0.36
Haemoglobin 45 0.19 0.21
Serum
Creatinine 45 0.05 0.77
Sodium 45 0.03 0.83
Potassium 44 0.04 0.78
Chloride: square root 45 0.09 0.57
Carbon dioxide 45 - 0.06 0.71
Albumin 33 0.24 0.18
Calcium 33 0.27 0.13
Bilirubin 36 - 0.33 0.05
Lactate dehydrogenase 32 0.22 0.23
Log of timeb 45 - 0.01 0.94
n, number of patients. r, Pearson product-moment correlation
coefficients. 'Data normalised where necessary by truncation of up to
three outliers and log transformation or use of square root. bLog
transformation of time from cisplatin administration to tumour re-
section.
Table IV Multiple stepwise regression model for the relationship
between patient characteristics and tumour platinum concentrations
Independent variable
Name Coefficient P
Intercept -4.18 0.01
Calcium 0.53 0.02
Bilirubin - 0.013 0.05
Chloridea 0.34 0.01
Type LMMb 0.24 0.02
Model: adjusted R2 = 0.39c; P = 0.002
"The square root of chloride was used since it (unlike chloride
itself) conformed to a normal distribution, as required by multiple
stepwise regression analysis. bType LMM = the group consisting of
primary brain lymphomas, meningiomas and medulloblastomas. CThe
adjusted R2 increased to 0.45 with the inclusion of 'other' tumour
sources along with the variables shown, but the P-value for 'other'
did not quite reach statistical significance (P = 0.057), and the P-
value for bilirubin increased to 0.07 with the inclusion of 'other'
sources. The data were equally well fitted by a model that included
each of tumour sources glioma, lung and head/neck (each of which
individually had a negative correlation with tumour platinum con-
centration, with P <0.05), serum calcium, chloride and bilirubin.
With the inclusion of these three tumour sources, the P-value for
bilirubin increased to 0.10.
Table V Tumour platinum concentrations: correlation with CT scan
characteristics in patients with intracranial tumour
Twuour plaktin
CT scan characteristic n r P
Volume of enhancement 17 0.34 0.18
Volume of 'necrosis' 17 - 0.19 0.47
'Necrotic'/total volume 16 - 0.27 0.30
Volume of oedema 17 0.39 0.12
Maximum enhancement intensity 17 0.29 0.27
Minimum enhancement intensity 17 0.35 0.17
Maximum oedema intensity 17 0.59 0.01
Proxnimity to brain surface 16 0.37 0.16
Proximity to ventricle 15 -0.13 0.64
n, number ofevaluable patients; r, Pearson product-moment correla-
tion coefficients; P, P-value.
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number of different free and bound platinum species were
present. Hence, it is possible that the conclusions we have
drawn regarding total platinum concentrations do not also
apply to the active species or to binding of drug to cyto-
toxcity-related intracellular targets. Despite this, we feel that
the information gained is important, since we have previously
found that both isplatin efficacy and toxicity are propor-
tional to total tissue platinum concentrations (reviewed in
Stewart, 1994a; Stewart, 1994), and since several cisplatin
metabolites are cytotoxic (Goel and HowelL 1989). Based on
these earlier observations, the concentration of active species
is probably geneally proportional to the total platinum con-
tent.
We made no attempt to correct tumour platinum concen-
trations for platinum concentrations in plasma since blood
generally accounts for kss than 5% of total tumour volume,
and since tumour platinum concentrations did not correlate
with any plasma platinum pharmacokinetic parameters. In
addition, when we divided tumour platinum concentrations
by the area under the concentration vs time curve from time
0 to the time of tumour removal to correct for possible
differences in exposure of the tumours to cisplatin, essentially
the same factors correlated with the resulting value as with
raw values of tumour platinum concentration (data not
shown).
In previous autopsy studies, we found no evidence that
drug concentrations in IC tumours were any lower than
those in EC tumours (reviewed in Stewart et al., 1994a;
Stewart, 1994). However, in these previous studies, there was
substantial variability between patients with respect to drug
dose, time from last treatment to death, etc. In this study,
drug doses were the same for all patients, and even after
correcting for the effect of other factors by multiple stepwise
regression analysis tumour platinum concentrations did not
vary significantly over the relatively narrow time span of
sample acquisition in this study. As in our previous studies,
we found no evidence in this study that entry ofasplatin into
IC tumours was any less than entry into EC tumours.
For reasons that are unclear, gliomas had lower platinum
concentrations than did any other IC or EC tumours. We
have previously noted higher or lower drug concentrations in
gliomas than in other IC tumours for other compounds as
well (reviewed Stewart et al., 1994a; Stewart, 1994).
Differences in this study may have been partially due to the
particularly low tumour platinum concentrations noted in
low-grade gliomas, but high-grade gliomas also had lower
platinum concentrations than did other tumours. It is pos-
sible that differences in cell membranes could partially
account for these results. For example, the fatty acid content
of cell membranes may alter cisplatin uptake and resistance
(Tunmer-Bosscha et al., 1989). While the high cisplatin
uptake into non-gliomas IC tumours indicates that the BBB
is not a major factor in cisplatin uptake into IC tumours,
differences observed between low-grade vs high-gade gliomas
suggest that BBB phenomena may, nevertheless, be playing a
minor role. While the BBB is largely disrupted within intra-
cranial tumours (Groothuis et al., 1981; Blasberg and
Groothuis, 1986), degree of contrast enh nt on CT
scans suggests that it may be less disrupted in low-grade than
high-grade gliomas (Tchang et al., 1977). While some
evidence suggests that the BBB plays a role in the resistance
of human IC tumours to chemotherapy, there are alternative
explanations for much ofthe evidence (reviewed in Stewart et
al., 1994a; Stewart, 1994). Tumour cell resistance is probably
a far more important reason for chemotherapy failure than is
inability of the drug to cross the intact BBB, and any barrier
might make relatively little difference for a highly cytotoxic
drug (Wodinsky et al., 1977). Hence both we (reviewed in
Stewart et al., 1983, 1986a-c, 1987a, 1989a, 1990a,b, 1994ac,
Feun et al., 1985; Stewart, 1987a,b, 1989, 1994) and several
other investigators (reviewed in Kolaric et al., 1981; Rosner
et al., 1983; Kantarajian et al., 1984; Stewart, 1989) have
elected to disregard the BBB when deciding which antineo-
plastic agents to investigate for therapeutic efficacy against
IC tumours.
We measured platinum concentration as a function of
tissue wet weight. It is possible that the differences we found
between different tumour types etc. could have been due to
varying protein and water content between different tumour
types. However, we have no data to suggest that this is the
case.
IC tumour platinum concentrations correlated significantly
with the CT scan intensity of oedema (i.e. maximum oedema
darkness relative to CSF) around the tumour on CT scan,
but did not correlate with intensity of enhancement. This
correlation continued to approach statistical signifi even
after correction for the effects of other factors by multiple
stepwise regression analysis, suggesting that the amount of
water and cisplatin dif ng out of a tumour into surround-
ing brain is dependent on somewhat different physiological
factors than is the amount of contrast dye retained in the
tumour. It is of interest that the concentration in brain
tumours of another water-soluble antineoplastic agent
(methotrexate) did correlate with intensity of me nt
(Neuwelt et al., 1980).
Tumour blood flow per gram of tissue (which is an impor-
tant determinant of the delivery of some dmgs to some
tissues; Dedrick et al., 1975) decreases as tumour size in-
creases (Shapiro, 1983). For lipid-insoluble drugs, cell mem-
brane factors may be more important determinants of drug
entry than is blood flow (Dedrick et al., 1975). The lack of a
correlation of estimated tumour size with tumour platinum
concentration, the low cisplatin concentrations seen in nor-
mal central nervous system and low-grade gliomas and the
somewhat higher tumour platinum concentrations we ob-
served in necrotic compared with viable tumours suggest that
this is so for cisplatin.
Cisplatin may enter tumour cells by both passive diffusion
and active transport (Gross and Scanlon, 1986; Kelley and
Rozencweig, 1989), and also may be actively pumped out of
some cells (Mann et al., 1990). The positive correlations in
multivariate analysis of tumour platinum concentrations with
serum calcium and chloride levels suggest that the active
transport of cisplatin into or out of cells may be affected by
these ions, or that these ions may alter passive diffusion of
cisplatin across cell membranes by altering membrane poten-
tials or membrane lipid metabolism. Of interest, we have
recently found that cisplatin uptake into a human lung
adenocarcinoma cell line also increases with increasig cal-
cium concentrations over a physiological range (Stewart et
al., 1994b). Furthermore, we have previously noted that
serm calcium levels correlated positively with cisplatin
neurotoxicity (Stewart et al., 1989b), but correlated
negatively with cisplatin renal toxcity (Stewart et al., 1987b),
suggesting that the effect of calcium on tissue platinum con-
centrations could vary from one tissue type to another. Other
ions such as copper and selenium also appear to reduce
cisplatin renal toxicity (Berry et al., 1984), but cisplatin
uptake into our human lung adenocarcinoma cell line in-
creased with increasing copper concentrations over a physio-
logical range (Stewart et al., 1994b). It was not possible to
measure serm copper levels as part ofthis study. Osmolarity
also affects cisplatin cell uptake and cytotoxicity (Goel and
Howel, 1989).
It is unknown whether the correlation between tumour
platinum concentrations and serum bilirubin is of any
physioogical signi . We previously noted that high
serum bilirubin is associated with increased cisplatin nephro-
toxicity (Stewart etal., 1987b). Liver attains higher platinum
concentrations than does almost any other organ in the
human body (Stewart et al., 1982). One might speculate that
hepatic conditions associated with increased serum bilirubin
levels also result in increased hepatic sequestration of cis-
platin. While such a hypothesis could explain the observed
negative association between serum biiirubin levels and
tumour platinmum concentrations, it would not explain our
previous observition of a positive association between high
serum bilirubin and augmented cisplatin nephrotoxicity
(Stewart et al., 1987b). Moreover, patients with hyper-
bilirubinaemia had higher kidney cortex platinum concentra-Tumour dsplain upte
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tions than did patients with normal serum bilirubin levels
(Stewart et al., 1994), indicating that, as with calcium, bill-
rubin could have differing effects on cisplatin uptake into
different types of tissue.
Perhaps the most likely explanation for the apparent effect
of bilirubin on tumour cell cisplatin uptake is that factors
associated with high bilirubin alter cellular passive drug
uptake by altering cell membrane lipid characteristics. We
(Popovic et al., 1992) and others (Timmer-Bosscha et al.,
1989) have found differences between cisplatin-sensitive and
-resistant cells with respect to cell membrane characteristics.
We have also found that cisplatin and its aquated species
interact chemically with some cell memnbrane lipid com-
ponents, and that phospholipid content may affect the ability
of cisplatin to diffuse passively through model membranes
(Taylor et al., 1992, 1993).
It is also possible that each of calcium, chloride and
bilirubin could have affected tumour cisplatin concentrations
by altering drug elimination, etc. However, this is unlikely to
be the case, in light of the fact that there was no significant
correlation between any plasma pharmacokinetic parameter
and tumour platinum concentrations.
In summary, the accumulation of cisplatin in tumours may
perhaps be more related to the tissue of origin of the tumour
and to physiological conditions than to whether the tumour
is intracranial or extracranial. We plan to conduct further
studies of factors affecting tumour cell cisplatin uptake.
Abbreviatioi AUC, area under the concentration vs time curve;
BAT, brain adjacent to tumour; BBB, blood-brain barrier; CSF.
cerebrospinal fluid, CT, computerised axial tomography; EC, extra-
cranial; IC, intracranial; NSCLC, non-small-cell lung cancer.
Acknoedgen.es
This study was supported in pan by a grant from the Ottawa
General Hospital Foundation. We would like to thank the pharmacy
staff and members of the Department of Anaesthesiology at the
Ottawa General Hospital for their help in conducting this study, and
Drs M Richard, G Laframboise, J Gerin-Lajoie, B Lefebvre and D
McKay for contributing patients to this study.
Referens
BERRY J-P, PAUWELLS C. TLOUZEAU S AND LESPINATS G. (1984).
Effect of selenium in combination with cis-diamminedichloro-
platinum II in the treatment of murine fibrosarcoma. Cancer
Res., 44, 2864.
BLASBERG RG AND GROOTHUIS DR. (1986). Chemotherapy of
brain tumors: physiological and pharmacokinetic considerations.
Semin. Oncol.. 13, 70-82.
DEDRICK RL. ZAHARKO DS. BENDER RA. BLEYER WA AND LUTZ
RJ. (1975). Pharmacokinetic considerations on resistance to
anticancer drugs. Cancer Chemother. Rep., 59, 795-804.
FEUN LG. YUNG W-KA, STEWART DJ, SAVARAJ N AND BODEY
GP. (1985). Phase II tnral of mitogauzone in malignant primary
brain tumors. Cancer Treat. Rep., 69, 329-330.
GAFFIN SL. (1979). Rapid solubilization of human body tissues and
tissue fluids for microdetermination of heavy metals. Clin. Toxi-
col.. 15, 293-300.
GOEL R AND HOWELL SB. (1989). Differential effects of cisplatin
metabolites on vanrous cell types. Proc. Am. Assoc. Cancer Res.,
30, 466.
GROOTHUIS DR, FISCHER JM. VICK NA AND BIGNER DD. (1981).
Comparative permeability of different glioma models to
horseradish peroxidase. Cancer Treat. Rep., 65 (Suppl. 2), 13-18.
GROSS R AND SCANLON KJ. (1986). Amino acid membrane trans-
port properties of L1210 cells resistant to cisplatin.
Chemioterapia, V, 37-43.
HASEGAWA H. USHIO Y. HAYAKAWA T. YAMADA K AND
MOGAMI H. (1983). Changes of the blood-brain barrier in ex-
perimental metastatic brain tumors. J. Neurosurg., 59, 304-310.
KANTARAJIAN H, FARHA PAM. SPITZER C, MURPHY WK AND
VALDIVIESO M. (1984). Systemic combination chemotherapy as
primary treatment of brain metastases from lung cancer. South.
Med. J., 77, 426-430.
KELLEY SL AND ROZENCWEIG M. (1989). Resistance to platinum
compounds: mechanisms and beyond. Eur. J. Cancer Clin.
Oncol., 25, 1135-1140.
KOLARIC K. ROTH A, JELICIC I AND MATKOVIC A. (1981). A
preliminary report on antitumorigenic activity of cis-dichloro-
diammineplatinum in metastatic brain tumors. Tumori, 67,
483-486.
LEVIN VA, CLANCY TP, AUSMAN JI AND RALL DP. (1972). Uptake
and distribution of 3H-methotrexate by the murine ependymob-
lastoma. J. Nati Cancer Inst., 48, 875-883.
LEVIN VA, FREEMAN-DOVE W AND LANDAHL HD. (1975).
Penneability characteristics of brain adjacent to tumors in rats.
Arch. Neurol., 32, 785-791.
LOO J AND RIEGELMAN S. (1970). Assessment of pharmacokinetic
constants from post infusion blood curves obtained after IV
infusion. J. Pharm. Sci., 59, 53-55.
MANN SC, ANDREWS PA AND HOWELL SB. (1990). Short-term
cis-diamminedichloroplatinum accumulation in sensitive and
resistant human ovarian carcinoma cells. Cancer Chemother.
Pharmacol., 25, 236-240.
NEUWELT EA, MARAVILLA KR. FRENKEL EP, BARNElT P, HILL S
AND MOORE RJ. (1980). Use of enhanced computerized tomog-
raphy to evaluate osmotic blood-brain barrier disruption.
Neurosurgery, 6, 49-56.
POPOVIC P, WONG PTT, GOEL R, EVANS WK, HOWELL SB. AUERS-
PERG N AND STEWART DJ. (1992). Pressure-tuning infrared
spectroscopy of cisplatin sensitive vs resistant ovarian cancer
cells. Proc. Am. Assoc. Cancer Res., 33, 464.
ROSNER D, NEMOTO T, PICKREN J AND LANE W. (1983). Manage-
ment of brain metastases from breast cancer by combination
chemotherapy. J. Neuro-Oncol., 1, 131-137.
ROWE-JONES D. (1969). Cytotoxic penetration and concentration in
huiman malignant tumors. Br. J. Surg., 56, 774-778.
SHAPIRO W. (1983). Blood brain barrier. Proceedings of the 13th
International Chemotherapy Congress, 208, 2-8.
SHUMAKER R. (1986). PKCALC: a BASIC interactive computer
program for the statistical and pharmacokinetic analysis of data.
Drug Metab. Rev., 17, 331.
STATISTICAL CONSULTANTS. (1986). PCNONLIN and NONLIN84:
software for the statistical analysis of nonlinear models. Am.
Stat., 40, 52.
STEWART DJ. (1987a). Intraarterial chemotherapy for brain tumors:
a summary of the Ottawa experience. In Brain Oncology, Biology,
Diagnosis, and Therapy. Chatel M, Darcel F, Pecker J. (eds)
pp. 397-402. Martinus Nijhoff: Dordrecht.
STEWART DJ. (1987b). Preliminary experience with menogaril in the
treatment of recurrent glioblastomas. In Brain Oncology, Biology,
Diagnosis, and Therapy. Chatel M, Darcel F, Pecker J. (eds)
pp. 423-426. Martinus Nijhoff: Dordrect.
STEWART DJ. (1989). The role of chemotherapy in the treatment of
gliomas in adults. Cancer Treat. Rev., 16, 129-160.
STEWART DJ. (1994). A critique of the role of the blood-brain
barrier in the chemotherapy of human brain tumors. J. Neuro-
Oncol., 20, 121-139.
STEWART DJ, BENJAMIN RS, LUNA M, SEIFERT WE AND LOO TL.
(1982). Human tissue distribution of platinum after cis-
diamminedichloroplatinum. Cancer Chemother. Pharmacol., 10,
51-54.
STEWART DJ, FEUN LG, MAOR M, LEAVENS M, BURGESS MA,
BENJAMIN RS AND BODEY SR GP. (1983). Weekly cisplatin
during cranial irradiation for malignant melanoma metastatic to
brain. J. Neuro-Oncol., 1, 49-52.
STEWART DJ, GRAHOVAC Z, RICHARD MT, BENOIT B, MAROUN
JA, HUGENHOLTZ H, RUSSELL N, DENNERY J, PETERSON E,
LUKE B, VENTUREYRA EG, GIRARD A AND HOPKINS HS.
(1986a). Phase I study of intraarterial mitomycin-C for recurrent
intracerebral tumors. In Biology of Brain Tumor, Walker MD,
Thomas DGT. (eds) pp. 469-473. Martinus Nijhoff: Boston.
STEWART DJ, MAROUN JA, PETERSON E, LAFRAMBOISE G,
RICHARD MT, BELANGER R AND GIRARD A. (1986b).
Adriamycin in the treatment of malignant meningiomas. In
Biology of Brain Tumor, Walker MD, Thomas DGT. (eds)
pp. 453-455. Martinus Nijhoff: Boston.
STEWART DJ, HUGENHOLTZ H, RUSSELL N, RICHARD MT, BENOrT
B, MAROUN JA, GRAHOVAC Z, GIRARD A AND NABWANGU
JF. (1986c). Phase II study of novantrone (mitoxanthrone hydro-
chloride) in adults with grade III-IV astrocytomas. In Biology of
Brain Twnor, Walker MD, Thomas DGT. (eds) pp. 411-413.
Martinus Nijhoff: Boston.DJ Stewart etad
STEWART DJ, GRAHOVAC Z, HUGENHOLTZ H, RUSSELL NA,
RICHARD MT. BENOIT BG, RIDING MD, DANJOUX C AND
MAROUN JA. (1987a). Intraarterial mitomycin-C for recurrent
brain metastases. Am. J Clin. Oncol., 10, 432-436.
STEWART DJ, MIKHAEL N, DULBERG C. NANJI A, MAROUN J.
VERMA S AND GADIA M. (1987b). Predictive factors for cisplatin
toxicity. Proc. ASCO, 6, 40.
STEWART DJ, MAROUN JA. VERMA S, PERRAULT D AND EAR-
HART RH. (1989a). Phase I study of weekly intravenous adminis-
tration of menogaril to adults with solid tumors. Am. J Clin.
Onc., 12, 511-518.
STEWART D, MONTPETIT V, MIKHAEL N, DULBERG C, VERMA S.
MAROUN J, REDMOND D, MOLEPO M, KEANEY M, DANCEA S
AND TRYPHONAS L. (1989b). Cisplatin (C) neuropathy (N).
Proc. Am. Assoc. Cancer Res., 30, 246.
STEWART D, GRAHOVAC Z, GIONET L. BENOIT AND HUGEN-
HOLTZ H. (1990a). Phase I study of intracarotid carboplatin.
Proc. ASCO, 9, 90.
STEWART DJ, VERMA S, MAROUN JA, ROBILLARD L AND EAR-
HART RH. (1990b). Phase I study of oral menogaril administered
on a once weekly schedule. Invest. New Drugs, 8, 43-52.
STEWART DJ, MOLEPO M, EAPEN L, MONTPETIT V, GOEL R,
WONG P, POPOVIC P, TAYLOR K AND RAAPHORST GP. (1994a).
Cisplatin and radiation in the treatment of tumors of the central
nervous system: pharmacological considerations and results of
early studies. Int. J. Radiat. Biol. Phys., 28, 531-542.
STEWART DJ, GREWAAL D, POPOVIC P, MOLEPO JM, SHIRAZI SFH
AND GOEL R (1994b). Alteration of cisplatin uptake into lung
cancer cell lines. Proc. Am. Assoc. Cancer Res., 35, 421.
STEWART DJ, DULBERG C, MOLEPO IM, MIKHAEL NZ, MONT-
PETIT VAJ, REDMOND MD AND GOEL R- (1994c). Factors
affecting human autopsy kidney cortex and kidney medulla
platinum concentrations after cisplatin. Cancer Chemother. Phar-
macol., 34, 14-22.
STEWART PA, HAYAKAWA K, FARRELL CL AND DEL MAESTRO
RF. (1987). Quantitative study of miicrovessel ultrastructure in
human peritumoral brain tissue. Evidence for a blood-brain
barrier defect. J. Neurosurg., 67, 697-705.
TATOR CH. (1976). Retention of tritiated methotrexate in a trans-
plantable mouse glioma. Cancer Res., 36, 3058-3066.
TAYLOR KD, GOEL R, STEWART DJ AND WONG PTT. (1992). Pres-
sure tuning infrared spectroscopic study of cisplatin induced
changes in phosphatidylserine model membrane. Proc. Am.
Assoc. Cancer Res., 33, 448.
TAYLOR KD, GOEL R, STEWART DJ AND WONG PTT. (1993). Pres-
sure tuning spectroscopic of cisplatin induced changes in a phos-
phatidylcholine model membrane. Proc. Am. Assoc. Cancer Res.,
34, 401.
TCHANG S, SCOTT G, TERBRUGGE K, MELANCON D, BELANGER
G, MILNER C AND ETHIER R. (1977). Computerized tomography
as a possible aid to histological grading of supratentorial gliomas.
J. Neurosurg., 46, 735-739.
TIMMER-BOSSCHA H, HOSPERS GAP, MEUER C, MULDER NH,
MUSKIET FAJ, MARTINI IA, UGES DRA AND DE VRIES EGE.
(1989). hifluence of docosahexaenoic acid on cisplatin resistance
in a human small cell lung carcinoma cell line. J. Natl Cancer
Inst., 81, 1069-1075.
VERMORKEN JB, VAN DER VUGH WJF, KLEIN I. GALL HE. VAN
GROENINGEN CJ, HART GAM AND PINEDO HM_ (1986).
Pharmacokinetics of free and total platinum species after rapid
and prolonged infusions of cisplatin. Clin. Pharmacol. Ther., 39,
136-144.
WODINSKY L MERKER PC AND VENFI1TI JM. (1977). Respon-
siveness to chemotherapy of mice with L1210 lymphoid leukemia
implanted in various anatomic sites. J. Natl Cancer Inst., 59, 405.